Defective splicing of the background K+ channel K2P5.1 by the pre-mRNA splicing inhibitor, pladienolide B in lectin-activated mouse splenic CD4+ T cells

J Pharmacol Sci. 2016 Nov;132(3):205-209. doi: 10.1016/j.jphs.2016.10.007. Epub 2016 Nov 3.

Abstract

The two-pore domain K+ channel K2P5.1 has been implicated in the pathogenesis of autoimmune diseases. We investigated the changes in K2P5.1 activity caused by a defect in normal pre-mRNA splicing in concanavalin A-activated mouse splenic CD4+ T cells. The pre-mRNA splicing inhibitor, pladienolide B (1 μM) markedly decreased full-length K2P5.1 transcription in activated CD4+ T cells, resulting in the disappearance of K2P5.1 activity and an imbalance in Th17 and Treg cytokines. These results suggest that the defect in K2P5.1 splicing by the pre-mRNA splicing inhibitor regulates pro- and/or anti-inflammatory cytokine production in K2P5.1-associated autoimmune diseases.

Keywords: K(+) channel; K(2P)5.1; Pre-mRNA splicing inhibitor.

MeSH terms

  • Animals
  • CD4-Positive T-Lymphocytes
  • Epoxy Compounds / pharmacology*
  • Macrolides / pharmacology*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Potassium Channels, Tandem Pore Domain / genetics*
  • Potassium Channels, Tandem Pore Domain / metabolism
  • RNA Precursors / genetics*
  • RNA Splicing / drug effects*
  • RNA Splicing / genetics

Substances

  • Epoxy Compounds
  • Macrolides
  • Potassium Channels, Tandem Pore Domain
  • RNA Precursors
  • pladienolide B